Curiox Biosystems Co., Ltd.

As of June 30, 2026, Curiox Biosystems Co., Ltd. carries a market capitalization of 827.74B, placing it among publicly traded companies globally. Its enterprise value stands at 817.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Curiox Biosystems Co., Ltd. has 17.12M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 143.58, and the price-to-book ratio stands at 16.90.

These figures are as of June 30, 2026. The EV/Sales ratio of 142.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 817.76B versus a market cap of 827.74B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Curiox Biosystems Co., Ltd. maintains a current ratio of 5.24, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.06, indicating moderate leverage, while an interest coverage ratio of -18.49 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Curiox Biosystems Co., Ltd. posted a negative return on equity (ROE) of -33.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -21.52, reflecting losses generated across the asset base. The company generates approximately 257.73M in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times Curiox Biosystems Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Curiox Biosystems Co., Ltd. recorded an income tax benefit of -35.88M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -12.82B and -12.78B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Curiox Biosystems Co., Ltd.'s stock has declined approximately 16.78% over the past 52 weeks. The 50-day moving average sits at 51,727.00, while the 200-day moving average is 77,688.25.

Over the twelve months ended June 30, 2026, Curiox Biosystems Co., Ltd. generated 5.73B in revenue and converted that into -12.78B in net income, yielding earnings per share of -750.49. EBITDA reached -10.22B, while operating income came in at -13.04B.

As of June 30, 2026, Curiox Biosystems Co., Ltd. holds 10.50B in cash and equivalents against 517.58M in total debt, resulting in a net debt position of -10.50B. Total book value stands at 48.98B, with working capital of 11.16B providing operational flexibility.

Curiox Biosystems Co., Ltd. produced -9.27B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -78.82M in capital expenditures, free cash flow totaled -9.35B - equivalent to -549.03 per share.

Over the twelve months ended June 30, 2026, Curiox Biosystems Co., Ltd. posted a gross margin of 49.05, reflecting its pricing power and cost economics. The operating margin of -227.43 and net profit margin of -222.85 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.35, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Curiox Biosystems Co., Ltd. shareholders.

Curiox Biosystems Co., Ltd.'s most recent stock split took place on August 6, 2024 with a 1:2 split ratio.

As of June 30, 2026, Curiox Biosystems Co., Ltd. has an Altman Z-Score of 104.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.